1921
Volume 103, Issue 1_Suppl
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

The Schistosomiasis Consortium for Operational Research and Evaluation (SCORE) was funded in 2008 to conduct research that would support country schistosomiasis control programs. As schistosomiasis prevalence decreases in many places and elimination is increasingly within reach, a sensitive and specific test to detect infection with and has become a pressing need. After obtaining broad input, SCORE supported Leiden University Medical Center (LUMC) to modify the serum-based antigen assay for use with urine, simplify the assay, and improve its sensitivity. The urine assay eventually contributed to several of the larger SCORE studies. For example, in Zanzibar, we demonstrated that urine filtration, the standard parasite egg detection diagnostic test for , greatly underestimated prevalence in low-prevalence settings. In Burundi and Rwanda, the circulating anodic antigen (CAA) assay provided critical information about the limitations of the stool-based Kato–Katz parasite egg-detection assay for in low-prevalence settings. Other SCORE-supported CAA work demonstrated that frozen, banked urine specimens yielded similar results to fresh ones; pooling of specimens may be a useful, cost-effective approach for surveillance in some settings; and the assay can be performed in local laboratories equipped with adequate centrifuge capacity. These improvements in the assay continue to be of use to researchers around the world. However, additional work will be needed if widespread dissemination of the CAA assay is to occur, for example, by building capacity in places besides LUMC and commercialization of the assay. Here, we review the evolution of the CAA assay format during the SCORE period with emphasis on urine-based applications.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution (CC-BY) License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.19-0819
2020-05-12
2020-09-22
Loading full text...

Full text loading...

/deliver/fulltext/14761645/103/1_Suppl/tpmd190819.html?itemId=/content/journals/10.4269/ajtmh.19-0819&mimeType=html&fmt=ahah

References

  1. Colley DG, Jacobson JA, Binder S, 2020. Schistosomiasis Consortium for Operational Research and Evaluation (SCORE): its foundations, development, and evolution. Am J Trop Med Hyg 103 (Suppl 1): 513.
    [Google Scholar]
  2. Colley DG et al., 2020. Evaluation, validation, and recognition of the point-of-care circulating cathodic antigen, urine-based assay for mapping Schistosoma mansoni infections. Am J Trop Med Hyg 103 (Suppl 1): 4249.
    [Google Scholar]
  3. Corstjens PL et al., 2014. Tools for diagnosis, monitoring and screening of Schistosoma infections utilizing lateral-flow based assays and upconverting phosphor labels. Parasitology 141: 18411855.
    [Google Scholar]
  4. Deelder AM, van Dam GJ, Kornelis D, Fillie YE, van Zeyl RJ, 1996. Schistosoma: analysis of monoclonal antibodies reactive with the circulating antigens CAA and CCA. Parasitology 112: 2135.
    [Google Scholar]
  5. Wilson AR, van Dam GJ, Kariuki TM, Farah IO, Deelder AM, Coulson PS, 2006. The detection limits for estimates of infection intensity in schistosomiasis mansoni established by a study in non-human primates. Int J Parasitol 36: 12411244.
    [Google Scholar]
  6. Agnew A, Fulford AJ, De Jonge N, Krijger FW, Rodriguez-Chacon M, Gutsmann V, Deelder AM, 1995. The relationship between worm burden and levels of a circulating antigen (CAA) of five species of Schistosoma in mice. Parasitology 111: 6776.
    [Google Scholar]
  7. Bustinduy AL et al., 2016. Population pharmacokinetics and pharmacodynamics of praziquantel in Ugandan children with intestinal schistosomiasis: higher dosages are required for maximal efficacy. mBio 7: e00227e00316.
    [Google Scholar]
  8. De Clercq D, Sacko M, Vercruysse J, Diarra A, Landoure A, vanden Bussche V, Gryseels B, Deelder A, 1995. Comparison of the circulating anodic antigen detection assay and urine filtration to diagnose Schistosoma haematobium infections in Mali. Trans R Soc Trop Med Hyg 89: 395397.
    [Google Scholar]
  9. Deelder AM et al., 1994. Quantitative diagnosis of Schistosoma infections by measurement of circulating antigens in serum and urine. Trop Geogr Med 46: 233238.
    [Google Scholar]
  10. Corstjens PL, Li S, Zuiderwijk M, Kardos K, Abrams WR, Niedbala RS, Tanke HJ, 2005. Infrared up-converting phosphors for bioassays. IEE Proc Nanobiotechnol 152: 6472.
    [Google Scholar]
  11. Corstjens PL, van Lieshout L, Zuiderwijk M, Kornelis D, Tanke HJ, Deelder AM, van Dam GJ, 2008. Up-converting phosphor technology-based lateral flow assay for detection of Schistosoma circulating anodic antigen in serum. J Clin Microbiol 46: 171176.
    [Google Scholar]
  12. Downs JA et al., 2012. Association of schistosomiasis and HIV infection in Tanzania. Am J Trop Med Hyg 87: 868873.
    [Google Scholar]
  13. van Dam GJ, de Dood CJ, Lewis M, Deelder AM, van Lieshout L, Tanke HJ, van Rooyen LH, Corstjens PL, 2013. A robust dry reagent lateral flow assay for diagnosis of active schistosomiasis by detection of Schistosoma circulating anodic antigen. Exp Parasitol 135: 274282.
    [Google Scholar]
  14. van Dam GJ, Bogitsh BJ, van Zeyl RJ, Rotmans JP, Deelder AM, 1996. Schistosoma mansoni: in vitro and in vivo excretion of CAA and CCA by developing schistosomula and adult worms. J Parasitol 82: 557564.
    [Google Scholar]
  15. van Grootveld R, van Dam GJ, de Dood C, de Vries JJC, Visser LG, Corstjens P, van Lieshout L, 2018. Improved diagnosis of active Schistosoma infection in travellers and migrants using the ultra-sensitive in-house lateral flow test for detection of circulating anodic antigen (CAA) in serum. Eur J Clin Microbiol Infect Dis 37: 17091716.
    [Google Scholar]
  16. Langenberg MCC et al., 2020. Single sex S. mansoni experimental infections in humans. Nat Med 26: 326332.
    [Google Scholar]
  17. Langenberg MCC, Hoogerwerf MA, Janse JJ, van Lieshout L, Corstjens P, Roestenberg M; Co HSIctt, 2019. Katayama syndrome without Schistosoma mansoni eggs. Ann Intern Med 170: 732733.
    [Google Scholar]
  18. Balahbib A et al., 2017. Selecting accurate post-elimination monitoring tools to prevent reemergence of urogenital schistosomiasis in Morocco: a pilot study. Infect Dis Poverty 6: 75.
    [Google Scholar]
  19. Sousa MS, van Dam GJ, Pinheiro MCC, de Dood CJ, Peralta JM, Peralta RHS, Daher EF, Corstjens P, Bezerra FSM, 2019. Performance of an ultra-sensitive assay targeting the circulating anodic antigen (CAA) for detection of Schistosoma mansoni infection in a low endemic area in Brazil. Front Immunol 10: 682.
    [Google Scholar]
  20. van Dam GJ, Odermatt P, Acosta L, Bergquist R, de Dood CJ, Kornelis D, Muth S, Utzinger J, Corstjens PL, 2015. Evaluation of banked urine samples for the detection of circulating anodic and cathodic antigens in Schistosoma mekongi and S. japonicum infections: a proof-of-concept study. Acta Trop 141: 198203.
    [Google Scholar]
  21. van Dam GJ et al., 2015. An ultra-sensitive assay targeting the circulating anodic antigen for the diagnosis of Schistosoma japonicum in a low-endemic area, People’s Republic of China. Acta Trop 141: 190197.
    [Google Scholar]
  22. Vonghachack Y et al., 2017. Comparison of novel and standard diagnostic tools for the detection of Schistosoma mekongi infection in Lao People’s Democratic Republic and Cambodia. Infect Dis Poverty 6: 127.
    [Google Scholar]
  23. de Water R, Van Marck EA, Fransen JA, Deelder AM, 1987. Ultrastructural localization of the circulating anodic antigen and the circulating cathodic antigen in the liver of mice infected with Schistosoma mansoni: a sequential study. Exp Parasitol 64: 499509.
    [Google Scholar]
  24. El-Dosoky I, Van Marck EA, Deelder AM, 1984. Presence of Schistosoma mansoni antigens in liver, spleen and kidney of infected mice: a sequential study. Z Parasitenkd 70: 491497.
    [Google Scholar]
  25. Polman K, Engels D, Fathers L, Deelder AM, Gryseels B, 1998. Day-to-day fluctuation of schistosome circulating antigen levels in serum and urine of humans infected with Schistosoma mansoni in Burundi. Am J Trop Med Hyg 59: 150154.
    [Google Scholar]
  26. Corstjens PL, Nyakundi RK, de Dood CJ, Kariuki TM, Ochola EA, Karanja DM, Mwinzi PN, van Dam GJ, 2015. Improved sensitivity of the urine CAA lateral-flow assay for diagnosing active Schistosoma infections by using larger sample volumes. Parasit Vectors 8: 241.
    [Google Scholar]
  27. Corstjens P, Hoekstra PT, de Dood CJ, van Dam GJ, 2017. Utilizing the ultrasensitive Schistosoma up-converting phosphor lateral flow circulating anodic antigen (UCP-LF CAA) assay for sample pooling-strategies. Infect Dis Poverty 6: 155.
    [Google Scholar]
  28. de Dood CJ, Hoekstra PT, Mngara J, Kalluvya SE, van Dam GJ, Downs JA, Corstjens P, 2018. Refining diagnosis of Schistosoma haematobium infections: antigen and antibody detection in urine. Front Immunol 9: 2635.
    [Google Scholar]
  29. King CH et al., 2020. Impact of different mass drug administration strategies for gaining and sustaining control of Schistosoma mansoni and Schistosoma haematobium infection in Africa. Am J Trop Med Hyg 103 (Suppl 1): 1423.
    [Google Scholar]
  30. Campbell CH et al., 2020. SCORE operational research on moving toward interruption of schistosomiasis transmission. Am J Trop Med Hyg 103 (Suppl 1): 5865.
    [Google Scholar]
  31. Knopp S et al., 2019. A 5-Year intervention study on elimination of urogenital schistosomiasis in Zanzibar: parasitological results of annual cross-sectional surveys. PLoS Negl Trop Dis 13: e0007268.
    [Google Scholar]
  32. Knopp S et al., 2012. Study and implementation of urogenital schistosomiasis elimination in Zanzibar (Unguja and Pemba islands) using an integrated multidisciplinary approach. BMC Public Health 12: 930.
    [Google Scholar]
  33. Knopp S et al., 2019. Evaluation of integrated interventions layered on mass drug administration for urogenital schistosomiasis elimination: a cluster-randomised trial. Lancet Glob Health 7: e1118e1129.
    [Google Scholar]
  34. Knopp S et al., 2015 Sensitivity and specificity of a urine circulating anodic antigen test for the diagnosis of Schistosoma haematobium in low endemic settings. PLoS Negl Trop Dis 9: e0003752.
    [Google Scholar]
  35. Clements MN et al., 2018. Latent class analysis to evaluate performance of point-of-care CCA for low-intensity Schistosoma mansoni infections in Burundi. Parasit Vectors 11: 111.
    [Google Scholar]
  36. Ruberanziza E et al., 2020. Nationawide remapping of Schistosoma mansoni infection in Rwanda using circulating cathodic antigen rapid test: taking steps towards elimination. Am J Trop Med Hyg 103: 315324.
    [Google Scholar]
  37. Jordan P, 1985. Schistosomiasis: the St. Lucia Project. Cambridge, United Kingdom: Cambridge University Press.
    [Google Scholar]
  38. Gaspard J, Usey MM, Fredericks-James M, Sanchez MJ, Atkins L, Campbell CH Jr, Corstjens PLAM, van Dam GJ, Colley DG, Secor WE, 2020. Survey of schistosomiasis in Saint Lucia: evidence for interruption of transmission. Am J Trop Med Hyg. Available at: https://doi.org/10.4269/ajtmh.19-0904.
    [Google Scholar]
  39. De Vlas SJ, Engels D, Rabello AL, Oostburg BF, Van Lieshout L, Polderman AM, Van Oortmarssen GJ, Habbema JD, Gryseels B, 1997. Validation of a chart to estimate true Schistosoma mansoni prevalences from simple egg counts. Parasitology 114: 113121.
    [Google Scholar]
  40. Hawkins KR, Cantera JL, Storey HL, Leader BT, de Los Santos T, 2016. Diagnostic tests to support late-stage control programs for schistosomisasis and soil-transmitted helminthiases. PLoS Negl Trop Dis 10: e0004985.
    [Google Scholar]
  41. Elliott AM et al., 2018. Ethical and scientific considerations on the establishment of a controlled human infection model for schistosomiasis in Uganda: report of a stakeholders’ meeting held in Entebbe, Uganda. AAS Open Res 1: 2.
    [Google Scholar]
  42. Roestenberg M, Mo A, Kremsner PG, Yazdanbakhsh M, 2017. Controlled human infections: a report from the controlled human infection models workshop, Leiden University Medical Centre 4–6 May 2016. Vaccine 35: 70707076.
    [Google Scholar]
  43. Siddiqui AJ et al., 2018. Sm-p80-based vaccine trial in baboons: efficacy when mimicking natural conditions of chronic disease, praziquantel therapy, immunization, and Schistosoma mansoni re-encounter. Ann N Y Acad Sci 1425: 1937.
    [Google Scholar]
  44. Downs JA, Corstjens PL, Mngara J, Lutonja P, Isingo R, Urassa M, Kornelis D, van Dam GJ, 2015. Correlation of serum and dried blood spot results for quantitation of Schistosoma circulating anodic antigen: a proof of principle. Acta Trop 150: 5963.
    [Google Scholar]
  45. Downs JA et al., 2017. Effects of schistosomiasis on susceptibility to HIV-1 infection and HIV-1 viral load at HIV-1 seroconversion: a nested case-control study. PLoS Negl Trop Dis 11: e0005968.
    [Google Scholar]
  46. Colley DG et al., 2020. Contributions of the Schistosomiasis Consortium for Operational Research and Evaluation (SCORE) to Schistosomiasis Control and Elimination: Key Findings and Messages for Future Goals, Thresholds, and Operational Research. Am J Trop Med Hyg 103 (Suppl 1): 125134.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.19-0819
Loading
/content/journals/10.4269/ajtmh.19-0819
Loading

Data & Media loading...

  • Received : 02 Nov 2019
  • Accepted : 09 Feb 2020
  • Published online : 12 May 2020
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error